Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03076372
Other study ID # MM-310-01-01-01
Secondary ID
Status Recruiting
Phase Phase 1
First received March 1, 2017
Last updated February 26, 2018
Start date February 22, 2017
Est. completion date December 2018

Study information

Verified date February 2018
Source Merrimack Pharmaceuticals
Contact Vasileios Askoxylakis, MD, PhD
Phone 617.441.7492
Email VAskoxylakis@merrimack.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 34
Est. completion date December 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Must have one of the following cancers, for which the patient has either received or been intolerant to all therapy known to confer clinical benefit

- Urothelial carcinoma

- Gastric/gastroesophageal junction/esophageal carcinoma (G/GEJ/E)

- Squamous Cell Carcinoma of the Head and neck (SCCHN)

- Ovarian cancer

- Pancreatic ductal adenocarcinoma (PDAC)

- Prostate adenocarcinoma (PAC)

- Non-small cell lung cancer (NSCLC)

- Small cell lung cancer (SCLC)

- Triple negative breast cancer (TNBC)

- Endometrial carcinoma

- Soft tissue sarcoma subtypes except GIST, desmoid tumors and pleomorphic rhabdomyosarcoma

- Able to provide informed consent, or have a legal representative able and willing to do so

- = 18 years of age

- Availability of a cancerous lesion amenable to biopsy and willing to undergo a pre-treatment biopsy

- ECOG Performance Status of 0 or 1

- Adequate bone marrow reserve as evidenced by:

- ANC > 1,500/µl (unsupported by growth factors) and

- Platelet count > 100,000/µl

- Hemoglobin > 9 g/dL

- Patients must have adequate coagulation function as evidenced by prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR) within normal institutional limits

- Adequate hepatic function as evidenced by:

- Serum total bilirubin = ULN

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN.

- Alkaline phosphatase = 2.5 x ULN, unless the elevated alkaline phosphatase is due to bone metastasis.

- In case alkaline phosphatase is >2.5 x ULN patients are eligible for inclusion if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 1.5 x ULN

- Adequate renal function as evidenced by a serum/plasma creatinine < 1.5 x ULN

- Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy to CTCAE v4.03 grade 1, baseline or less, except for alopecia

- Women of childbearing potential or fertile men and their partners must be willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 6 months following the last dose of MM-310.

Exclusion Criteria:

- Prior treatment with docetaxel within 6 months of study enrollment

- Pregnant or lactating

- Treatment with systemic anticoagulation (e.g. warfarin, heparin, low molecular weight heparin, anti-Xa inhibitors, etc.) except aspirin

- Any evidence of hematemesis, melena, hematochezia, = grade 2 hemoptysis, or gross hematuria

- Any history of hereditary bleeding disorders

- Presence of an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing, which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome. At the discretion of the investigator, patients with tumor fever may be enrolled

- Known CNS metastases

- Known hypersensitivity to the components of MM-310, or docetaxel

- Prior treatment with MM-310

- Received treatment, within 28 days or 5 half-lives, whichever is shorter, prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state and all prior clinically significant treatment related toxicities have resolved to Grade 1 or baseline

- Received other recent antitumor therapy including any standard chemotherapy or radiation within 14 days (or have not yet recovered from any actual toxicities of the most recent therapy) prior to the first scheduled dose of MM-310

- Received any anti-cancer drug known to have anti-VEGF/VEGFR activity within a period of 5 half-lives of this drug (e.g. 100 days for bevacizumab, 75 days for ramucirumab) prior to the first scheduled dose of MM-310

- Clinically significant cardiac disease, including: NYHA Class III or IV congestive heart failure, unstable angina, acute myocardial infarction within six months of planned first dose, arrhythmia requiring therapy (including torsades de pointes, with the exception of extrasystoles, minor conduction abnormalities, or controlled and well treated chronic atrial fibrillation)

- Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the investigator

- Patients who received organ or allogeneic bone marrow or peripheral blood stem cell transplants

- Chronic use of corticosteroids more than 10mg daily prednisone equivalent during the past 4 weeks prior to planned start of MM-310

- Concomitant use of strong inhibitors of CYP3A

- Patients with peripheral neuropathy of grade 2 or higher

Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Squamous Cell
  • Carcinoma, Transitional Cell
  • Endometrial Carcinoma
  • Endometrial Neoplasms
  • Gastric Carcinoma
  • Head and Neck Neoplasms
  • Lung Neoplasms
  • Non-small Cell Lung Cancer
  • Ovarian Cancer
  • Ovarian Neoplasms
  • Pancreatic Ductal Adenocarcinoma
  • Prostate Adenocarcinoma
  • Prostatic Neoplasms
  • Sarcoma
  • Small Cell Lung Cancer
  • Small Cell Lung Carcinoma
  • Soft Tissue Sarcoma
  • Solid Tumors
  • Squamous Cell Carcinoma of the Head and Neck
  • Stomach Neoplasms
  • Triple Negative Breast Cancer
  • Triple Negative Breast Neoplasms
  • Urothelial Carcinoma

Intervention

Drug:
MM-310
MM-310

Locations

Country Name City State
United States Roswell Park Cancer Institute Buffalo New York
United States Duke University Durham North Carolina
United States Mayo Clinic Rochester Minnesota
United States University California San Francisco San Francisco California
United States Honor Health Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Merrimack Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors. 18 months
Secondary Serum levels of analytes that comprise MM-310 18 months
Secondary Adverse event profile using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 18 months
Secondary Presence of human anti-human antibodies to MM-310 18 months
Secondary Objective responses based on RECIST v1.1 or other relevant criteria 18 months
Secondary Disease Control Rate 18 months
Secondary Progression Free Survival 18 months
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2